Trellus Management Company LLC Has $821,000 Position in Pacific Biosciences of California (PACB)

Share on StockTwits

Trellus Management Company LLC lessened its stake in Pacific Biosciences of California (NASDAQ:PACB) by 79.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 111,000 shares of the biotechnology company’s stock after selling 417,415 shares during the quarter. Pacific Biosciences of California comprises approximately 1.9% of Trellus Management Company LLC’s holdings, making the stock its 18th biggest holding. Trellus Management Company LLC’s holdings in Pacific Biosciences of California were worth $821,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PACB. FNY Investment Advisers LLC acquired a new position in shares of Pacific Biosciences of California in the 4th quarter valued at $26,000. Hudock Capital Group LLC acquired a new position in shares of Pacific Biosciences of California in the 4th quarter valued at $29,000. Clean Yield Group acquired a new position in shares of Pacific Biosciences of California in the 4th quarter valued at $37,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Pacific Biosciences of California by 37.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,580 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 2,628 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in shares of Pacific Biosciences of California in the 3rd quarter valued at $107,000. Institutional investors own 75.18% of the company’s stock.

In other news, insider Kathy Ordonez sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $7.54, for a total value of $188,500.00. Following the transaction, the insider now owns 68,750 shares of the company’s stock, valued at approximately $518,375. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 13.40% of the company’s stock.

Shares of PACB opened at $7.19 on Friday. Pacific Biosciences of California has a fifty-two week low of $2.02 and a fifty-two week high of $7.84. The company has a quick ratio of 5.74, a current ratio of 6.65 and a debt-to-equity ratio of 0.11.

A number of equities analysts have weighed in on PACB shares. Cowen started coverage on shares of Pacific Biosciences of California in a report on Friday, October 19th. They issued an “outperform” rating and a $6.50 price target on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $8.00 price target on shares of Pacific Biosciences of California in a report on Sunday, October 21st. ValuEngine upgraded shares of Pacific Biosciences of California from a “buy” rating to a “strong-buy” rating in a report on Friday, November 2nd. Finally, BidaskClub upgraded shares of Pacific Biosciences of California from a “hold” rating to a “buy” rating in a report on Saturday, November 3rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $5.64.

TRADEMARK VIOLATION NOTICE: “Trellus Management Company LLC Has $821,000 Position in Pacific Biosciences of California (PACB)” was originally reported by Macon Daily and is owned by of Macon Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://macondaily.com/2019/02/10/trellus-management-company-llc-has-821000-position-in-pacific-biosciences-of-california-pacb.html.

Pacific Biosciences of California Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Featured Article: Investing in Dividend Stocks

Want to see what other hedge funds are holding PACB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacific Biosciences of California (NASDAQ:PACB).

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply